Compendia and anticancer therapy under medicare

Katherine Tillman, Brijet Burton, Louis B. Jacques, Steve E. Phurrough

Research output: Contribution to journalReview article

Abstract

In 1993, Congress directed the Medicare program to refer to 3 existing published compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia Drug Information for the Health Professional (USP-DI), and American Hospital Formulary Service Drug Information (AHFS-DI), to identify unlabeled but medically accepted uses of drugs and biologicals in anticancer chemotherapy regimens. Public discussion during the preceding years had centered on whether to designate unlabeled uses of anticancer treatments as experimental and thus outside the scope of Medicare benefits. American Medical Association Drug Evaluations and USP-DI subsequently ceased publication, and the Medicare program faced increasing calls to revise the list of acceptable compendia, as authorized in the statute. In 2007, the Centers for Medicare & Medicaid Services used its regulatory authority to establish a publicly transparent process to revise the list. The Centers for Medicare & Medicaid Services considered 5 requests in 2008 and added National Comprehensive Cancer Network Drugs and Biologies Compendium, DRUCDEX, and Clinical Pharmacology to the list of compendia. DrugPoints was not added, and AMA-DE was removed. Because of the potential for conflicts of interest to lead to biased judgments, the 2008 Medicare Improvements for Patients and Providers Act has a provision that explicitly prohibits inclusion of compendia that do not have a publicly transparent process for evaluating therapies and identifying potential conflicts of interest.

Original languageEnglish (US)
Pages (from-to)348-350
Number of pages3
JournalAnnals of Internal Medicine
Volume150
Issue number5
DOIs
StatePublished - Mar 3 2009
Externally publishedYes

Fingerprint

Medicare
Drug Evaluation
American Medical Association
Conflict of Interest
Medicaid
Drug Information Services
Therapeutics
Hospital Formularies
Pharmaceutical Preparations
Pharmacopoeias
Clinical Pharmacology
Publications
Drug Therapy
Health
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Tillman, K., Burton, B., Jacques, L. B., & Phurrough, S. E. (2009). Compendia and anticancer therapy under medicare. Annals of Internal Medicine, 150(5), 348-350. https://doi.org/10.7326/0003-4819-150-5-200903030-00109

Compendia and anticancer therapy under medicare. / Tillman, Katherine; Burton, Brijet; Jacques, Louis B.; Phurrough, Steve E.

In: Annals of Internal Medicine, Vol. 150, No. 5, 03.03.2009, p. 348-350.

Research output: Contribution to journalReview article

Tillman, K, Burton, B, Jacques, LB & Phurrough, SE 2009, 'Compendia and anticancer therapy under medicare', Annals of Internal Medicine, vol. 150, no. 5, pp. 348-350. https://doi.org/10.7326/0003-4819-150-5-200903030-00109
Tillman, Katherine ; Burton, Brijet ; Jacques, Louis B. ; Phurrough, Steve E. / Compendia and anticancer therapy under medicare. In: Annals of Internal Medicine. 2009 ; Vol. 150, No. 5. pp. 348-350.
@article{20e49b260e0c47efad53fe77cd867d65,
title = "Compendia and anticancer therapy under medicare",
abstract = "In 1993, Congress directed the Medicare program to refer to 3 existing published compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia Drug Information for the Health Professional (USP-DI), and American Hospital Formulary Service Drug Information (AHFS-DI), to identify unlabeled but medically accepted uses of drugs and biologicals in anticancer chemotherapy regimens. Public discussion during the preceding years had centered on whether to designate unlabeled uses of anticancer treatments as experimental and thus outside the scope of Medicare benefits. American Medical Association Drug Evaluations and USP-DI subsequently ceased publication, and the Medicare program faced increasing calls to revise the list of acceptable compendia, as authorized in the statute. In 2007, the Centers for Medicare & Medicaid Services used its regulatory authority to establish a publicly transparent process to revise the list. The Centers for Medicare & Medicaid Services considered 5 requests in 2008 and added National Comprehensive Cancer Network Drugs and Biologies Compendium, DRUCDEX, and Clinical Pharmacology to the list of compendia. DrugPoints was not added, and AMA-DE was removed. Because of the potential for conflicts of interest to lead to biased judgments, the 2008 Medicare Improvements for Patients and Providers Act has a provision that explicitly prohibits inclusion of compendia that do not have a publicly transparent process for evaluating therapies and identifying potential conflicts of interest.",
author = "Katherine Tillman and Brijet Burton and Jacques, {Louis B.} and Phurrough, {Steve E.}",
year = "2009",
month = "3",
day = "3",
doi = "10.7326/0003-4819-150-5-200903030-00109",
language = "English (US)",
volume = "150",
pages = "348--350",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Compendia and anticancer therapy under medicare

AU - Tillman, Katherine

AU - Burton, Brijet

AU - Jacques, Louis B.

AU - Phurrough, Steve E.

PY - 2009/3/3

Y1 - 2009/3/3

N2 - In 1993, Congress directed the Medicare program to refer to 3 existing published compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia Drug Information for the Health Professional (USP-DI), and American Hospital Formulary Service Drug Information (AHFS-DI), to identify unlabeled but medically accepted uses of drugs and biologicals in anticancer chemotherapy regimens. Public discussion during the preceding years had centered on whether to designate unlabeled uses of anticancer treatments as experimental and thus outside the scope of Medicare benefits. American Medical Association Drug Evaluations and USP-DI subsequently ceased publication, and the Medicare program faced increasing calls to revise the list of acceptable compendia, as authorized in the statute. In 2007, the Centers for Medicare & Medicaid Services used its regulatory authority to establish a publicly transparent process to revise the list. The Centers for Medicare & Medicaid Services considered 5 requests in 2008 and added National Comprehensive Cancer Network Drugs and Biologies Compendium, DRUCDEX, and Clinical Pharmacology to the list of compendia. DrugPoints was not added, and AMA-DE was removed. Because of the potential for conflicts of interest to lead to biased judgments, the 2008 Medicare Improvements for Patients and Providers Act has a provision that explicitly prohibits inclusion of compendia that do not have a publicly transparent process for evaluating therapies and identifying potential conflicts of interest.

AB - In 1993, Congress directed the Medicare program to refer to 3 existing published compendia, American Medical Association Drug Evaluations (AMA-DE), United States Pharmacopoeia Drug Information for the Health Professional (USP-DI), and American Hospital Formulary Service Drug Information (AHFS-DI), to identify unlabeled but medically accepted uses of drugs and biologicals in anticancer chemotherapy regimens. Public discussion during the preceding years had centered on whether to designate unlabeled uses of anticancer treatments as experimental and thus outside the scope of Medicare benefits. American Medical Association Drug Evaluations and USP-DI subsequently ceased publication, and the Medicare program faced increasing calls to revise the list of acceptable compendia, as authorized in the statute. In 2007, the Centers for Medicare & Medicaid Services used its regulatory authority to establish a publicly transparent process to revise the list. The Centers for Medicare & Medicaid Services considered 5 requests in 2008 and added National Comprehensive Cancer Network Drugs and Biologies Compendium, DRUCDEX, and Clinical Pharmacology to the list of compendia. DrugPoints was not added, and AMA-DE was removed. Because of the potential for conflicts of interest to lead to biased judgments, the 2008 Medicare Improvements for Patients and Providers Act has a provision that explicitly prohibits inclusion of compendia that do not have a publicly transparent process for evaluating therapies and identifying potential conflicts of interest.

UR - http://www.scopus.com/inward/record.url?scp=61449191773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449191773&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-150-5-200903030-00109

DO - 10.7326/0003-4819-150-5-200903030-00109

M3 - Review article

C2 - 19221368

AN - SCOPUS:61449191773

VL - 150

SP - 348

EP - 350

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -